Neuroanesthesia & neurocritical care
Dexmedetomidine Prevents Chronic Incisional Pain After Brain Tumor Resection: A Secondary Analysis of the Randomized Control Trial
Primary resultResult — go to the resultRelative risk 0.55 95% CI 0.38–0.80Authors' conclusion
Prophylactic intraoperative dexmedetomidine infusion reduces the incidence of chronic incisional pain as well as acute pain score after elective brain tumor resections.
Study context
- Population
- Patients undergoing elective brain tumor resection (craniotomy)included in final analysis
- Participants
- 252 patients
- Comparison
- Intraoperative dexmedetomidine vs placebo
- Dexmedetomidinen = 128
- Placebon = 124reference
- Primary endpoint
- Incidence of incisional pain (NRS score >0)
- Follow-up
- 3 months after craniotomy
Methodological detailsdouble-blind, placebo-controlled, January 2021 to December 2021
- Double-blind
- Placebo-controlled
- January 2021 to December 2021
Primary result
As reported in the abstract
Relative risk
0.55
95% CI 0.38–0.80
P = 0.001
Events by treatment group
Dexmedetomidine vs Placebo
RR 0.55 (95% CI 0.38–0.80); P = 0.001
Secondary outcomes
| Outcome | P value |
|---|---|
| SF-MPQ-2 total sensory and neuropathic pain descriptor scores · 3 months after craniotomyDexmedetomidine vs Placebo · lower in the Dexmedetomidine group | P = 0.01 |
| SF-MPQ-2 total sensory and neuropathic pain descriptor scores · 3 months after craniotomyDexmedetomidine vs Placebo · lower in the Dexmedetomidine group | P = 0.023 |
Acute pain severity on movement · first 3 days after surgery
- Lower in the Dexmedetomidine group vs Placebo (all adjusted P < .01)
Sleep quality
- Did not differ between groups
Original publication
Dexmedetomidine Prevents Chronic Incisional Pain After Brain Tumor Resection: A Secondary Analysis of the Randomized Control Trial. Anesth Analg. Published 12 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →